Volume 28, Number 5—May 2022
Research
Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
Figure 2

Figure 2. Adjusted vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 infection in persons 16–59 years of age, by week, September 6, 2021–January 1, 2022 (A), and >60 years of age, by week, August 9, 2021–January 1, 2022 (B), Israel. Adjustments were performed for sex, age, and epidemiologic week. Error bars represent 95% CIs.